The release of the snapshot containing the respective simulations can be found here: <https://github.com/Open-Systems-Pharmacology/Cimetidine-Metformin-DDI>

The Cimetidine and metformin DDI was initially  developed and published by [Hanke 2020](#5-references) and adjusted later on to PK-Sim V11.  The DDI was characterized by competitive inhibition of OCT1, OCT2 and MATE1. 

The Cimetidine-Metformin interaction was evaluated using 3 clinical DDI studies including 4 clinical DDI scenarios  ([Boehringer 2018](#references), [Somogyi 1987](#references), [Wang 2008](#references)).


| DataID | Transporter | Perpetrator / victim     | Study design                                                                                                                                              | Comment | Clinical study                      |
|---:|:---|:--------|:----------------------------------------------|:---|:------|
|  17006|  MATE1/OCT | Cimetidine/Metformin | Cimetidine: **400** mg po, tablet, qid Metformin: **10** mg po, solution, <sup>a</sup>   | 1 h dose gap      | [Boehringer 2018](#references)        |
|  17007 | MATE1/OCT | Cimetidine/Metformin | Cimetidine: **400** mg po, tablet, qid Metformin: **250** mg po, tablet, qd, fed    |    0 h dose gap     | [Somogyi](#references)        |
|   17008 | MATE1/OCT   | Cimetidine/Metformin| Cimetidine: **400** mg po, tablet, qid Metformin: **500** mg po, solution  |1h dose gap         | [Boehringer 2018](#references)       |
|  17009 | MATE1/OCT   | Cimetidine/Metformin | Cimetidine: **400** mg po, -, bid Metformin: **10** mg po single dose |   2 h dose gap     | [Wang 2008](#references)        |

**po**: oral
**qid**: four times daily
**qd**: once daily
**bid**: twice daily
-: not given
<sup>a</sup> 10 mg metformin together with 0.25 mg digoxin, 1 mg furosemide and 10 mg rosuvastatin
